Tazeen Ahmad

is there any reason to think that a result like that would not have been replicated with AMVUTTRA

how long do you think it would take for patients to appreciate something like that, be it the base, switching from vutrisiran to nuceresiran when it becomes available

as you're thinking about or currently negotiating 2026 status, can you share with us some of the feedback that you're getting from payers

how you're thinking about net price for AMVUTTRA and gross-to-net moving forward

who are the prescriber base? Are they people that have already had previous experience with AMVUTTRA

how long you think it's going to take to establish payer policies after the approval of vutri

I wanted to ask your thoughts on how you are thinking about the impact to Trodelvy sales in triple negative

how do you see this coexisting with Opzelura in the commercial space? What's been your experience with marketing and this indication so far

can you just give us your sense of what the uptake is in the current approved indications? And the average number of tubes that are being used

How important is that going to be for people to believe that you have convinced efficacy as a stand-alone

maybe this is for Pablo on some read-through from the mCALR data that you saw from ET and what to maybe expect to see for MF

You had guided the data for this calendar year. Is that still the plan? And if so, can you just give us a little bit of guidance on what level of data

can you give us a sense of how you got to guidance for this calendar year? Specifically, how are you thinking about the number of tubes

do you think is differentiated in your program? Do you think that you'll need to show a visual acuity benefit

on the CF pipeline, I just wanted to get a sense of what data you plan on showing in the second half of the year for 828

what your thoughts are on the read-through from this positive IgAN study that you provided top line for recently

what results do you think would provide your mind

what the FDA had seen thus far that let them give you the confidence to start the filing early and get this breakthrough designation

Is it your plan to launch with the auto-injector when you go live on IgAN

I'm just curious as to what the profile of the patients are that are the earliest onboarders and where in the treatment regimen are these scripts being written

for this year, just to clarify, are you expecting to see cannibalization of ALYFTREK from ALYFTREK

I just wanted to get a sense of expectations for the type 1 diabetes data that you're set to show